- Published on
KembaraXtra- Medicine – Alpha-1-Antitrypsin Deficiency
Alpha-1-antitrypsin deficiency (AATD) is an inherited genetic disorder caused by deficiency or dysfunction of the protease inhibitor alpha-1-antitrypsin (AAT). The condition most commonly results from homozygous carriage of the SERPINA1 Z allele (PI*ZZ genotype). This mutation leads to production of an abnormal AAT protein (Z-AAT) that accumulates within hepatocytes while circulating levels of functional AAT are markedly reduced. The resulting imbalance predisposes affected individuals to early-onset pulmonary emphysema, chronic obstructive pulmonary disease (COPD), and progressive liver disease, including cirrhosis and hepatocellular carcinoma.
Alpha-1-antitrypsin deficiency is underrecognized but accounts for approximately 1% to 5% of COPD cases in the United States, with an estimated prevalence of 1 in 2000 to 5000 individuals. The disorder is inherited in an autosomal codominant fashion. The normal M allele is present in about 95% of the population, while the deficient Z allele occurs in 1% to 2% and the S allele in 2% to 3%. Severe deficiency most often occurs in individuals with the ZZ genotype, while those with SZ or MZ genotypes may have partial deficiency, with increased risk of lung disease—particularly in smokers. Approximately 1 in 10 individuals of European descent carries at least one abnormal allele.
Clinical manifestations vary depending on genotype and environmental exposures. The lungs are most commonly affected, with patients developing early-onset, lower-lobe–predominant panlobular emphysema, often before age 45 and sometimes in the absence of smoking. Symptoms resemble typical COPD and include progressive dyspnea, chronic cough, and sputum production. Bronchiectasis may also be present. Smoking significantly accelerates lung damage and worsens prognosis. Liver involvement may present as neonatal cholestasis, chronic hepatitis, cirrhosis, or hepatocellular carcinoma in both children and adults. A rare dermatologic manifestation is panniculitis, characterized by painful, inflammatory subcutaneous nodules caused by unopposed proteolysis in the skin.
The pathophysiology of AATD involves loss of antiprotease protection in the lungs and toxic accumulation of mutant AAT protein in hepatocytes. In the lungs, reduced AAT levels fail to adequately inhibit neutrophil elastase, leading to destruction of alveolar elastin and development of emphysema. In the liver, disease results not from deficiency but from intracellular retention of misfolded Z-AAT, which triggers hepatocellular injury, inflammation, and fibrosis. Not all individuals with AAT deficiency develop clinical disease, but smoking is the strongest modifiable risk factor for lung involvement.
Diagnosis should be suspected in patients with early-onset COPD, emphysema without typical risk factors, or basilar-predominant emphysema on imaging. Unexplained liver disease, panniculitis, bronchiectasis, poorly responsive asthma, or c-ANCA–associated vasculitis should also prompt evaluation. Initial testing includes measurement of serum alpha-1-antitrypsin levels, followed by genotyping to identify specific alleles. Pulmonary function testing typically shows airflow obstruction consistent with COPD. Imaging with chest radiography or high-resolution computed tomography often demonstrates lower-lobe–predominant emphysema and may reveal bronchiectasis.
Management begins with nonpharmacologic interventions, most importantly complete avoidance of smoking, which dramatically reduces the risk and progression of lung disease. Patients should also avoid occupational and environmental exposures that damage the lungs and receive routine vaccinations, including influenza, pneumococcal, pertussis, and SARS-CoV-2 vaccines. Acute COPD exacerbations are treated similarly to those in patients without AATD.
For chronic management, the therapeutic goal is to raise serum AAT levels above the protective threshold of approximately 50 mg/dL. Currently, the only FDA-approved disease-specific therapy is intravenous alpha-1-antitrypsin augmentation therapy, which uses pooled human AAT to slow progression of emphysema. This treatment requires lifelong administration, is costly, and does not reverse established lung damage nor improve liver disease. Patients with end-stage lung or liver disease may be candidates for organ transplantation, which can be life-saving and curative for the affected organ.
Prognosis depends on genotype, degree of deficiency, and environmental factors. Among patients with severe AATD, respiratory failure is the leading cause of death, followed by cirrhosis and liver-related complications. Early diagnosis, smoking cessation, and appropriate specialty care significantly improve outcomes. Referral to clinicians experienced in managing AATD is recommended, including pulmonology, hepatology, and transplant centers when indicated.
Alpha-1-antitrypsin deficiency remains substantially underdiagnosed, and expert guidelines recommend testing all patients with COPD, emphysema, irreversible asthma, unexplained liver disease, bronchiectasis, or panniculitis, as well as first-degree relatives of affected individuals. Early recognition allows for risk reduction, appropriate monitoring, and timely intervention to prevent irreversible organ damage.
0 Comments
